Galecto Biotech AB has divulged new galectin-3 (LGALS3) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, fibrosis and cardiovascular, eye, metabolic, cerebrovascular and inflammatory disorders, among other disorders.

Akita University and Tohoku University have described curcumin derivatives acting as β-catenin (CTNNB1) and NF-κB activation inhibitors reported to be useful for the treatment of cancer.

Tohoku University has divulged quinoline compounds acting as histamine N-methyltransferase (HNMT) inhibitors reported to be useful for the treatment of narcolepsy, Alzheimer's disease and attention deficit hyperactivity disorder (ADHD).

Beta Pharma Inc. has patented pyridopyrimidines acting as GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.

Bionanosim Ltd. has discovered cannabinoid CB1 receptor antagonists reported to be useful for the treatment of metabolic disorders.

Infex Therapeutics Ltd. has divulged nonstructural protein 3 (nsp3, PL-PRO) macrodomain (Mac1) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome.

Biomedcode Hellas SA has synthesized carboxamide derivatives reported to be useful for the treatment of inflammatory disorders.

Xuanzhu Pharma Co. Ltd. has discovered new tricyclic compounds acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1) inhibitors reported to be useful for the treatment of cancer.

Medshine Discovery Inc. has identified thiophene compounds acting as lysine-specific histone demethylase 1A (LSD1) inhibitors reported to be useful for the treatment of cancer.